{"title":"血液恶性肿瘤患者的静脉血栓栓塞与死亡率","authors":"Kristen M. Sanfilippo, Tzu-Fei Wang","doi":"10.4081/btvb.2024.119","DOIUrl":null,"url":null,"abstract":"Mortality and venous thromboembolism (VTE) are major risks for patients with hematological malignancies. However, they are commonly underrepresented in major clinical trials of VTE. Treatment decisions are further complicated by the unique characteristics they frequently exhibit, such as thrombocytopenia. In addition to discussing treatment challenges, knowledge gaps, and future directions, our goal in this narrative review is to provide an overview of the epidemiology and risk factors of mortality in patients with hematological malignancies and VTE.","PeriodicalId":517891,"journal":{"name":"Bleeding, Thrombosis and Vascular Biology","volume":"27 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Venous thromboembolism and mortality in patients with hematological malignancies\",\"authors\":\"Kristen M. Sanfilippo, Tzu-Fei Wang\",\"doi\":\"10.4081/btvb.2024.119\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mortality and venous thromboembolism (VTE) are major risks for patients with hematological malignancies. However, they are commonly underrepresented in major clinical trials of VTE. Treatment decisions are further complicated by the unique characteristics they frequently exhibit, such as thrombocytopenia. In addition to discussing treatment challenges, knowledge gaps, and future directions, our goal in this narrative review is to provide an overview of the epidemiology and risk factors of mortality in patients with hematological malignancies and VTE.\",\"PeriodicalId\":517891,\"journal\":{\"name\":\"Bleeding, Thrombosis and Vascular Biology\",\"volume\":\"27 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bleeding, Thrombosis and Vascular Biology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/btvb.2024.119\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bleeding, Thrombosis and Vascular Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/btvb.2024.119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Venous thromboembolism and mortality in patients with hematological malignancies
Mortality and venous thromboembolism (VTE) are major risks for patients with hematological malignancies. However, they are commonly underrepresented in major clinical trials of VTE. Treatment decisions are further complicated by the unique characteristics they frequently exhibit, such as thrombocytopenia. In addition to discussing treatment challenges, knowledge gaps, and future directions, our goal in this narrative review is to provide an overview of the epidemiology and risk factors of mortality in patients with hematological malignancies and VTE.